Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity.

Authors:
Jing H; Ren Y; Zhou Y; Xu M; Krizkova S and 6 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.08.020

PMCID:
PMC10692490

PMID:
38045041

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors have no conflicts of interest to declare."

Evidence found in paper:

"This work was supported by the Young Elite Scientists Sponsorship Program by Tianjin (No. 0701320001, China), Major Special Projects (No. 0402080005, China), National Key R&D Program of China (No. 2020YFC1512304, China) and National Natural Science of China (Nos. 82273873, 31971106, and 81372124, China) and the Czech Health Council (AZV NU12J-08–00043, Czech). Moreover, we express our gratitude to Zhi Li (School of Pharmaceutical Science and Technology, Tianjin University, China) for the assistance in the FACS experiments."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025